Abstract
Objective With the growing number of older people in the Norwegian population and the associated rapid rise in dementia and cognitive impairment, novel and more efficient methodologies are needed to facilitate research, improve diagnostic triage and deliver effective brain health interventions in the community. Methods: PROTECT-Norge is an online, remote cohort study in adults aged 50 and over. At-home assessments of cognition are completed annually using validated computerized neuropsychological tests (including Paired Associate Learning, Self-Ordered Search, Digit Span and Verbal Reasoning). Demographic data (age, gender, ethnicity, education, height, weight), medical and lifestyle information are also collected. Results: The current article describes analysis of baseline data from the first 3000 participants recruited to PROTECT-Norge (74.5% female, mean age 64.1 sd 7.7). It demonstrates that established risk factors for dementia such as Body Mass Index > 30, hypertension, smoking, and hearing loss are associated with significant detriments on cognitive performance on the computerized neuropsychological test battery. The level of data capture was excellent, and 94% of participants agreed to be contacted for further research programmes. Conclusion: This data shows excellent feasibility of the PROTECT-Norge cohort, demonstrating high completion rates and accessibility for people with early cognitive impairment. PROTECT-Norge represents a tremendous opportunity for cost-efficient, large-scale brain health research and potentially for clinical digital cognitive health programmes.
Key Points
PROTECT Norge is an online cohort study focusing on cognitive assessment and dementia risk factors in a population of Norwegian adults aged 50 and over.
The study utilizes validated computerized neuropsychological test battery for annual at-home assessments, in addition to capturing demographic, medical, and lifestyle data.
Study findings indicate significant associations between established dementia risk factors (e.g., obesity, hypertension, smoking, hearing loss) and poorer cognitive performance, highlighting the potential for early intervention strategies.
High participant engagement and willingness for further research involvement highlights PROTECT Norge’s feasibility and potential for large-scale brain health initiatives and clinical trials, using its built-in clinical trials infrastructure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PROTECT Norge has received funding from the National Collaboration Group for Health Research in the Specialist Health Care Services (Nasjonal samarbeidsgruppe for helseforskning i spesialisthelsetjenesten)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study use data from the PROTECT Norge Study (https://www.protect-norge.no/), launched in September 2020, approved by the Regional Committee for Medical and Health Research Ethics, West (Ref #2019/478).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: jon.arild.aakre{at}sus.no
Email: martha.therese.gjestsen{at}sus.no
Email: C.Ballard{at}exeter.ac.uk
Email: A.M.J.Corbett{at}exeter.ac.uk
Email: daarsland{at}gmail.com
Email: E.Pickering{at}exeter.ac.uk
Email: anastasia.ushakova{at}sus.no
Conflicting Interests: The authors declare that they have no competing interests.
Data availability: This study is based on data collected in the PROTECT Norge study: https://www.protect-norge.no/. PROTECT Norge data can be shared with investigators outside the PROTECT team after request.
Ethical statement: This study use data from the PROTECT Norge Study (https://www.protect-norge.no/), launched in September 2020, approved by the Regional Committee for Medical and Health Research Ethics, West (Ref #2019/478).
Data Availability
This study is based on data collected in the PROTECT Norge study: https://www.protect-norge.no/. PROTECT Norge data can be shared with investigators outside the PROTECT team after request.
